drugset / Trial / NCT07612215
Elacestrant in Advanced Triple Positive Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study to assess the safety and efficacy of elacestrant, a selective estrogen receptor degrader (SERD) and dual biologic therapy, trastuzumab and pertuzumab, in patients with triple-positive breast cancer with and without an ESR1 mutation.
Timeline
- Start
- 2026-05-13
- Primary completion
- 2029-05
- Completion
- 2030-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacestrant | Other / unclassified | 345 mg | Oral |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |